Previous Issue
Volume 2, September
 
 

J. Pharm. BioTech Ind., Volume 2, Issue 4 (December 2025) – 1 article

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
18 pages, 1413 KB  
Article
Enhanced Ocular Retention and Anti-Allergic Efficacy of a Novel HA–Ectoine–CMC Eye Drop for Dry Eye Disease Management
by Jon Andrade del Olmo, Alejandro Melero, Ander Pino, Nagore Martínez de Cestafe, Oihane Gartziandia, Miguel Ucelay López de Heredia, Josune Torrecilla, Laura Gómez, Sandra Benito Cid, José María Alonso and Raúl Pérez González
J. Pharm. BioTech Ind. 2025, 2(4), 16; https://doi.org/10.3390/jpbi2040016 - 11 Oct 2025
Viewed by 99
Abstract
Dry eye disease (DED) is a multifactorial ocular surface disorder that significantly affects vision and quality of life. While artificial tears are the standard first-line therapy, their effectiveness is limited by the complex pathophysiology of DED. This study evaluated DayDrop® Triple Action, [...] Read more.
Dry eye disease (DED) is a multifactorial ocular surface disorder that significantly affects vision and quality of life. While artificial tears are the standard first-line therapy, their effectiveness is limited by the complex pathophysiology of DED. This study evaluated DayDrop® Triple Action, a novel formulation combining hyaluronic acid (HA), ectoine, and carboxymethylcellulose (CMC), designed to enhance tear film stability and ocular surface protection. Physicochemical and rheological properties were assessed, including viscosity, pseudoplasticity, and viscoelastic behaviour under dynamic conditions, along with ectoine release over 24 h. An in vitro allergic conjunctivitis model using conjunctival fibroblasts exposed to a pro-allergic cytokine cocktail was employed to examine immunomodulatory effects. DayDrop® Triple Action demonstrated high viscosity with pronounced pseudoplasticity and stable viscoelasticity, supporting improved mucoadhesion. The formulation provided sustained ectoine release and exhibited a positive immunomodulatory effect, likely linked to ectoine’s preferential hydration mechanism, which stabilizes membranes and reduces inflammatory signalling. These findings suggest that DayDrop® Triple Action integrates viscoelastic optimization, osmoprotection, and targeted anti-inflammatory action, offering a promising non-pharmacological strategy for managing DED and allergic ocular surface disorders. Full article
Show Figures

Graphical abstract

Previous Issue
Back to TopTop